H2O2 promotes immunogenic cell death, preserves T cell function, and selectively reduces immunosuppressive Mφ2. Collectively, these findings provide a strong rationale for combining H2O2 with IR to alleviate hypoxia-driven immunosuppression and improve clinical outcomes in solid tumors.

1 month ago

Journal

IFNG (Interferon, gamma) • MRC1 (Mannose Receptor C-Type 1)

hydrogen peroxide (KRC-01)

2ms

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 (clinicaltrials.gov)

P1, N=70, Recruiting, Kortuc, Inc. | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

cisplatin • hydrogen peroxide (KRC-01)

2ms

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer (clinicaltrials.gov)

P2, N=184, Recruiting, Institute of Cancer Research, United Kingdom | Trial primary completion date: Apr 2027 --> Jun 2028

2 months ago

Trial primary completion date • First-in-human

hydrogen peroxide (KRC-01)

1year

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer (clinicaltrials.gov)

P2, N=184, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Nov 2027 --> Apr 2028 | Trial primary completion date: Nov 2027 --> Apr 2027

1 year ago

Trial completion date • Trial primary completion date

hydrogen peroxide (KRC-01)

over2years

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 (clinicaltrials.gov)

P1, N=70, Not yet recruiting, Kortuc, Inc. | Phase classification: P1/2 --> P1

over 2 years ago

Phase classification • Metastases

cisplatin • hydrogen peroxide (KRC-01)

over2years

KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer (clinicaltrials.gov)

P2, N=184, Recruiting, Institute of Cancer Research, United Kingdom | Trial completion date: Dec 2026 --> Nov 2027 | Trial primary completion date: Dec 2026 --> Nov 2027

over 2 years ago

Trial completion date • Trial primary completion date • Metastases

hydrogen peroxide (KRC-01)

almost3years

KORTUC, a novel hydrogen peroxide‑based radiosensitizer for the enhancement of brachytherapy in patients with unresectable recurrent uterine cervical cancer. (PubMed, Oncol Lett)

Based on this finding, KORTUC with external irradiation is considered to be an optimal treatment strategy for patients with newly diagnosed LRCC this disease. Additionally, KORTUC may be an effective radiation response enhancer in multiple cancer types in which locoregional control after RT alone remains poor.

almost 3 years ago

Journal

hydrogen peroxide (KRC-01)

3years

Combined treatment with direct hydrogen peroxide administration and irradiation promotes an abscopal effect in mouse models (AACR 2023)

Indeed, H2O2 has been clinically developed as a radiosensitizer (development code: KRC-01)... Intratumoral H2O2 administration enhanced the abscopal effect through activating antitumor immunity by RT.

3 years ago

Preclinical

CD8 (cluster of differentiation 8)

hydrogen peroxide (KRC-01)